Imatinib mesylate (IM) is used in the targeted therapy of chronic myelogenous leukemia and gastrointestinal stromal tumors. It is well tolerated and leads to no higher incidence of hemorrhagic events than other therapies. Of 87 patients we treated with IM for a minimum of 3 months, 10 patients (11%) developed unilateral or bilateral conjunctival hemorrhage (CH). No other hemorrhagic events were observed during follow-up, except for CH recurrence in 6 cases (7%). Because there was no other obvious reason for such a high incidence of CH, we hypothesize drug hypersensitivity or ocular irritation induced by IM treatment.
|Titolo:||Conjunctival hemorrhagic events associated with imatinib|
|Autori interni:||LAMBERTENGHI DELILIERS, GIORGIO (Ultimo)|
VENER, CLAUDIA (Secondo)
REDA, GIANLUIGI (Penultimo)
|Settore Scientifico Disciplinare:||Settore MED/15 - Malattie del Sangue|
|Data di pubblicazione:||2007|
|Enti collegati al convegno:||Italian Society of Hematology|
|Digital Object Identifier (DOI):||10.1532/IJH97.E0741|
|Appare nelle tipologie:||01 - Articolo su periodico|
File in questo prodotto:
- PubMed Central loading...